acp-196 and Atherosclerosis

acp-196 has been researched along with Atherosclerosis* in 1 studies

Other Studies

1 other study(ies) available for acp-196 and Atherosclerosis

ArticleYear
Bruton's Tyrosine Kinase inhibition by Acalabrutinib does not affect early or advanced atherosclerotic plaque size and morphology in Ldlr
    Vascular pharmacology, 2023, Volume: 150

    Atherosclerosis is characterized by the accumulation of lipids and immune cells, including mast cells and B cells, in the arterial wall. Mast cells contribute to atherosclerotic plaque growth and destabilization upon active degranulation. The FcεRI-IgE pathway is the most prominent mast cell activation route. Bruton's Tyrosine Kinase (BTK) is involved in FcεRI-signaling and may be a potential therapeutic target to limit mast cell activation in atherosclerosis. Additionally, BTK is crucial in B cell development and B-cell receptor signaling. In this project, we aimed to assess the effects of BTK inhibition on mast cell activation and B cell development in atherosclerosis. In human carotid artery plaques, we showed that BTK is primarily expressed on mast cells, B cells and myeloid cells. In vitro, BTK inhibitor Acalabrutinib dose-dependently inhibited IgE mediated activation of mouse bone marrow derived mast cells. In vivo, male Ldlr

    Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Atherosclerosis; Humans; Immunoglobulin E; Male; Mice; Plaque, Atherosclerotic; Protein-Tyrosine Kinases

2023